Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Pulmonary Infections
•
Bronchiectasis
Do you integrate inhaled colistimethate sodium into existing treatment regimens for patients with bronchiectasis and PSAR infection?
PROMIS-I and II
Related Questions
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
How do you manage persistent pseudomonas positive sputum a patient with non-CF bronchiectasis who has chronic sputum production but is otherwise asymptomatic?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Do you prolong IV therapy or reduce the number of antibiotic agents for patients with pulmonary NTM infections who have completed induction IV therapy and cannot access oral antibiotic therapy due to cost?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
Are there situations where you would consider treating E faecalis or E faecium that grows from a respiratory culture?
Have you incorporated the use of MycoTOX profiles into your clinical practice and, if so, in what capacity?
Should the RSV vaccine be administered to pregnant mothers even if it is not seasonally circulating but they are 32-36 weeks pregnant?
Do you treat patients with culture positive mycobacterium abscessus if they are asymptomatic and do not have progression on imaging?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
